laurabbook@gmail.com

*July 2025* In a presentation at the 26th Annual International Lung Cancer Congress, Heather Wakelee, MD, highlighted therapeutic avenues in the second line after the development of resistance to first-line osimertinib (Tagrisso) or combination therapies for patients with non–small cell lung cancer (NSCLC) harboring EGFR mutations.1 These included secondary mutation–targeted therapies; chemotherapy-based treatment, including the…

*July 2025* In an interview with Targeted Oncology, Jacob Sands, MD, medical oncologist at Dana-Farber Cancer Institute, discusses the integration of datopotamab deruxtecan (Dato-DXd; Datroway) into the treatment landscape for EGFR-mutant non–small cell lung cancer (NSCLC). The recent FDA approval of Dato-DXdoffers a new therapeutic avenue for patients with EGFR-sensitizing mutations in…

*July 2025* Abstract The discovery of activating mutations in the epidermal growth factor receptor (EGFR) gene has revolutionized the management of lung cancer, enabling the development of targeted tyrosine kinase inhibitors (TKIs). These therapies offer improved survival and reduced side effects compared with conventional treatments. Recent advancements have significantly reshaped…

*June 2025* Targeted OncologyTM: How did the MARIPOSA trial (NCT04487080) assess patients receiving amivantamab (Rybrevant) plus lazertinib (Lacluze) vs osimertinib (Tagrisso) forinterstitial lung disease (ILD)? Xiuning Le, MD, PhD: I think it's based on both . Nowadays, for ILD in most of the clinical trials, they will take our investigator…

*June 2025* Abstract Third-generation tyrosine kinase inhibitors are effective treatment of EGFR-mutated NSCLC. After an initial response, patients on this therapy ultimately develop resistance leading to disease progression. One of the resistance mechanisms is histological transformation to SCLC. There is no standard of care for the management of transformed SCLC. Given the rarity of transformed SCLC,…

*July 2025* Highlights --Mutations were more easily detected in CSF than in plasma of NSCLC leptomeningeal metastasis. --Genes enriched in CSF are altered in multiple oncogenic signaling pathways. --CSF exhibits significantly greater copy number variations and missense mutations than plasma. --Furmonertinib combined with bevacizumab, and high-dose pemetrexed for IVC can…